Technology About the authors
Dr. Fran Conti-Ramsden Dr. Fran Conti-Ramsden is a UK Obstetrics and Gynaecology registrar and Chadburn Clinical Lecturer at KCL passionate about transforming women’s
From left to right: Hebe Davies-Colley, Senior Project Manager HIN South London, Natasha Bell, Practice Development Midwife at King’s College Hospital, Ruth Bradbury, Senior Programme Manager HIN South London, Dijana Vilic, Head of Clinical Scientific Computing at Guy’s and St Thomas’ NHS Foundation Trust, Dr. Katy Kuhrt, Obstetrics & Gynaecology Registrar and Post Doctoral Research Fellow at King’s College London.
perhaps the most bracing for founders. She was emphatic that AI for women’s health is not a philanthropic niche but a high-growth vertical that must meet the same venture fundamentals as any other.
What her firm scrutinises more heavily in this space is threefold. First, data integrity, because in a field with a documented evidence gap, an AI trained on inadequate data will underperform and can systematically reproduce the very disparities it claims to address; she looks for clinical rigour that is structurally embedded through prospective trials, institutional partnerships and peer-reviewed outputs. Second, longitudinal and representative data as a genuine moat, since the company that builds that infrastructure first creates a compounding advantage that is hard to replicate. Third, privacy and trust, given how sensitive women’s health data is. Her closing challenge was one the whole room felt: on a five-to-six-year investment horizon, she needs conviction that adoption by hard-pressed providers will happen.
The consensus: evidence is the moat If the day reached a conclusion, it was this. For a regulated clinical company, academic depth and commercial value are not in tension; they are the same thing. Speakers from very different vantage points: a Trust computing lead, a regulatory specialist, a regulator and an investor, converged on the view that there is no shortcut through clinical validation, that a broadly scoped tool is a liability rather than a feature, and that the hardest part of building AI for women’s health is rarely the model. It is the data foundations, the governance, the integration into overstretched services, and the patience to generate evidence that stands up.
None of this is an argument for slowing
down. The equity gaps described in the opening session carry a real and continuing human cost, and the maternity safety agenda gives the NHS every reason to look seriously at tools that extend the reach of its workforce. It is an argument for a specific kind of speed: moving fast on well-scoped problems, with representative data, embedded clinical rigour and early engagement with the Trusts and regulators who will ultimately decide whether a tool reaches a patient. For clinical service leaders evaluating AI in women’s health, the day’s discussions translate into a short set of questions worth asking of any supplier. What is the precisely stated intended purpose, and do the claims being made trace to it? Was the training and validation data representative of the women this service actually cares for, by sex, ethnicity and clinical presentation? What is the plan for monitoring performance after deployment, when scanners change, populations shift and models drift? Does the tool save money or time in a way the service can measure? And has the company engaged with clinical computing, information governance and safety teams early, or is it arriving with a finished product and an expectation of a fast yes? The final consensus was quieter but may
matter most. Progress in this field depends on clinicians, academics, founders, regulators and funders being in the same room often enough to understand each other.
Building that community is what this event set
out to start, and judging by the conversations that continued long into the evening, there is an appetite for it. The open question the room left with is the one worth ending on - how do we move fast enough to matter, without cutting the corners that women’s health can least afford?
CSJ 50
www.clinicalservicesjournal.com I November 2026
health through technology and innovation. Combining NHS clinical experience with an MRC- funded PhD, recent NHS Clinical AI fellowship and commercial role as Chief Medical Officer at Megi health, she works at the intersection of clinical medicine, data science, technology and AI. Her current programme of research focuses on the intersection of healthcare and technology; leveraging advances such as smartphone based vital signs capture and large language models to drive forward scalable innovation in maternal cardiovascular care. She has published over 20 peer-reviewed manuscripts (See gScholar, h-index 14), including award-winning work recognised by Hypertension Journal. She was awarded an AI visionary award in 2025 by Health Innovation KSS and was the recipient of the 2024 International Society for the Study of Hypertension in Pregnancy Zuspan prize.
Dr. Nina Sesto Dr. Nina Sesto, PhD, MBA, is the Co-Founder and CEO of Megi Health, a regulated AI medical device company transforming female cardiovascular
care, starting in pregnancy. Combining a PhD in molecular biology from Institut Pasteur with an MBA from HEC Paris and Wharton and a Singularity University fellowship, she works at the intersection of clinical medicine, data science, technology and business. Megi grew out of a cardiovascular hospital built and still run by her family, where she led digital health and scaled a MedTech business from the ground up. Her current focus is on the intersection of healthcare and technology, harnessing advances such as continuous smartphone- based vital signs capture and large language models to drive scalable innovation in maternal cardiovascular care, in partnership with institutions including King’s College London and the NHS and with growing operations in the US. Her vision is a world where women’s hearts are understood on their own terms, not as an afterthought to medicine built around male physiology, delivered through care that is continuous, equitable and always within reach.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71